Search Results - "Orel, N F"

Somatostatin receptor type 2 expression in Merkel cell carcinoma as a prognostic factor by Orlova, K.V., Delektorskaya, V.V., Vishnevskaya, Y.V., Kondratieva, T.T., Orel, N.F., Markovich, A.A., Demidov, L.V., Subramanian, S.

Get full text

SOMATOSTATIN RECEPTORS AS POTENTIALTHERAPEUTIC TARGETS IN THE TREATMENT OF ADVANCED ADRENOCORTICAL CANCER. A CASE REPORT by Kolomeytseva, A. A., Delektorskaya, V. V., Orel, N. F., Emelianova, G. S., Bokhian, V. Y., Fedenko, A. A.

“…Background. Adrenocortical cancer (ACC) is a rare malignancy of the adrenal cortex. Therapeutic options for advanced ACC are limited. It is necessary to study…”
Get full text

Potential for use sunitinib in pancreatic neuroendocrine tumors by Markovich, A. A., Kuznetsova, A. A., Gorbunova, V. A., Orel, N. F., Odintsova, A. S., Emelyanova, G. S., Kuzminov, A. E.

“…The treatment efficacy and toxicity profile was evaluated in 33 patients with highly differentiated neuroendocrine tumors NEO (G1, G2), who received sunitinib…”
Get full text

Cancer patient management during the COVID-19 pandemic Training module. Version 2 from 30.04.2020 by Poddubnaya, I. V., Sychev, D. A., Abuzarova, G. R., Allakhverdiev, A. K., Arkhiri, P. P., Babicheva, L. G., Baranova, M. P., Volkova, M. I., Ignatova, A. V., Kashurnikov, A. Iu, Kniazev, R. I., Kolyadina, I. V., Komarov, I. G., Kriukov, A. V., Levitskaia, N. V., Liadov, V. K., Malikhova, O. A., Nered, S. N., Orel, N. F., Podviaznikov, S. O., Sagaidak, I. V., Sarmanaeva, R. R., Stilidi, I. S., Trofimova, O. P., Tumian, G. S., Kharitonova, T. V.

“…The training module was developed by the staff of the department under the leadership of the head. Department of Academician of RAS, Professor I.V. Poddubnoy…”
Get full text

PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT by Emelianova, G. S., Orel, N. F., Gorbunova, V. A., Kolomeytseva, A. A., Kuznetsova, A. A., Kuzminov, A. E., Fedenko, A. A.

“…Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options…”
Get full text

Esthesioneuroblastoma: clinical course, long-term results of treatment by Tabolinovskaya, T. D., Mudunov, A. M., Alieva, S. B., Orel, N. F., Komarova, L. E., Oganyan, E. R., Pustynskiy, I. N., Khasanov, R. A., Aketova, T. A., Pirogova, N. A.

“…This rare tumor from a group of neuroendocrine neoplasms was studied. The material for the study was the data of 78 patients with esthesioneuroblastoma who had…”
Get full text

Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin by Khokhlova, S V, Cherkasova, M V, Orel, N F, Limareva, S V, Bazaeva, I Ia, Gorbunova, V A

“…Given the high rate of recurrence of ovarian cancer, the search for new therapeutic strategies are topical issue. According to various studies the…”
Get more information

Study on efficacy and toxicity of new combined regimen "taxoter + cisplatin + 5-fluorouracil" in disseminated and locally-spread stomach cancer. Comparative analysis of tolerance and efficacy in patients younger and older than 65 years by Besova, N S, Orel, N F, Borisova, T A, Markovich, A A, Zaguzina, N N, Gorbunova, V A

“…The aim of our study was to evaluate the efficacy and safety of 3-drugs regimen: T 75 mg/m2 d2 + P 75 mg/m2 d2 + F 500 mg/m2 x 3h d 1-3 every 28 days. 31…”
Get more information

Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study by Gorbonova, V A, Egorov, G N, Perevodchikova, N I, Orel, N F

Get more information

Interferon α (IFN-α) vs. the combination IFN-α and octreotide LAR in the treatment of patients with well differentiated neuroendocrine tumors (NET) of various localizations by G S Yemelyanova, A E Kuzminov, N F Orel, A A Markovich, A A Kuznetsova, V A Gorbunova

“…It is still unknown whether the combination of IFN-α with octreotide has benefit compared with IFN-α alone. We compared efficacy and toxicyty of IFN-α and…”
Get full text

The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation by A A Kolomeytseva, G S Yemelyanova, V A Gorbunova, N F Orel, N I Perevodchikova, V Yu Bokhyan, A A Fedenko

“…A combination of etoposide, doxorubicin and cisplatin plus mitotane (EPD-M) is the most effective regimen in patients with advanced adrenocortical carcinoma…”
Get full text

Experience of use of everolimus and long-acting somatostatin analogues combination in highly differentiated (G1-G2) neuroendocrine tumors by A A Markovich, A E Kuzminov, N F Orel, A S Odintsova, G S Emelyanova, V A Gorbunova

“…Everolimus is the targeted drug approved for the treatment of neuroendocrine tumors (NET). Efficacy of everolimus in combination with octreotide-depo has been…”
Get full text

Prognostic significance of dynamics of biochemical markers of neuroendocrine tumors during treatment with biotherapy by G S Emelianova, V A Gorbunova, N V Lubimova, N F Orel, A A Markovich, V U Selchuk

“…Dynamic of biochemical markers of neuroendocrine tumors (chromogranin A, serotonin, 5-hydroxyindoleacetic acid) are predictive factorsof biotherapy efficacy…”
Get full text

Lanreotide for the treatment of patients with disseminated high-grade neuroendocrine tumors: the experience of application in case of unsatisfactory tolerability of octreotide by Emelyanova, G.S., Kuzminov, A.E., Orel, N.F., Odintsova, A.S., Markovich, A.A., Kuznetsova, A.A., Gorbunova, V.A.

“…Somatostatin analogs plays a key role in the treatment of disseminated well-differentiated functioning and nonfunctioning neuroendocrine tumors (NET). Its…”
Get full text

Vozmozhnost' ispol'zovaniya ingibitorov tirozinkinazy v lechenii bol'nykh nemelkokletochnymrakom legkogo s mutatsiyami gena retseptora epidermal'nogo faktora rosta (obzor) by N F Orel

Get full text

The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer by M V Cherkasova, S V Khokhlova, S V Limareva, I Y Bazaeva, N F Orel, V A Gorbunova, I V Poddubnaya

“…Given the high rate of recurrence of epithelial ovarian cancer after radical treatment is necessary to improve the therapeutic approach to its treatment. New…”
Get full text

In vitro detection of metastases of small-cell pulmonary carcinoma to the bone marrow using monoclonal antibodies by Goncharskaya, M. A., Orel, N. F., Perevodchikova, N. I., Solov'eva, E. A.

Get full text

Toxicity of trabectedin-based combinations in the treatment of different malignant tumors by M V Cherkasova, S V Khokhlova, S V Limareva, N F Orel, V A Gorbounova, I V Poddubnaya, N V Lyubimova

“…Antitumor activity of trabectedin as a monotherapy in different solid tumors (soft tissue sarcoma, ovarian cancer, breast cancer, melanoma) contributed to…”
Get full text

Delayed hypersensitivity reaction in patients with metastatic testicular teratoblastoma by Orel, N F

“…In 41 patients with testicular teratoblastoma the cell-mediated immunity was studied by delayed hypersensitivity skin testing. Skin tests for DNCB, PPD,…”
Get more information

Vozmozhnosti targetnoy terapiipri lechenii neyroendokrinnykhopukholey zheludochno-kishechnogotrakta i podzheludochnoy zhelezy by N F Orel, A A Markovich

Get full text